Skip to main content

Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer

The Original Article was published on 24 May 2011

Correction

After the publication of this work [1], we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’.

We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.

References

  1. Chen : Clusterin confers gmcitabine resistance in pancreatic cancer. World J Surg Oncol. 2011, 9: 59-10.1186/1477-7819-9-59.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bomin Yan.

Additional information

The online version of the original article can be found at 10.1186/1477-7819-9-59

Qingfeng Chen, Zhengkun Wang, Kejun Zhang contributed equally to this work.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Chen, Q., Wang, Z., Zhang, K. et al. Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer. World J Surg Onc 11, 149 (2013). https://doi.org/10.1186/1477-7819-11-149

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1477-7819-11-149